Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Cyclosporine 0.05% for Pterygia Inflammation
NCT00383396Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Countries
- 1
01
Overview
Phase 4 trial of CyclAGel in pterygium, sponsored by Janssen Pharmaceutical. Primary endpoint: Prevention of Recurrent Inflammation. Status: completed.
02
Drugs
CyclAGel
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT00383396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383396.